"I think it would be better for those of us who have the disease not to be ashamed".

Insights from people living with chronic hepatitis B virus infection and healthcare workers

providing HBV care in Kilifi, Kenya.

Short title: Insights on HBV care in Kilifi, Kenya

Louise O Downs[1,2], Juliet Odhiambo[2], Mwanakombo Zaharani[2], Oscar Chirro[2], Benson Safari[2], Janet Seeley[3,4],

Philippa C Matthews [5,6,7], Nadia Aliyan[8] and Nancy Kagwanja[2].

1. Nuffield Department of Medicine, University of Oxford, UK

2. KEMRI-Wellcome Trust Research Programme, Kilifi, Kenya

3. London School of Hygiene and Tropical Medicine, Keppel St, London, WC1E 7HT, UK

4. Africa Health Research Institute, KwaZulu-Natal, South Africa

5. The Francis Crick Institute, 1 Midland Road, London NW1 1AT, UK

6. Division of Infection and Immunity, University College London, London, UK

7. University College London Hospital, 235 Euston Road, London NW1 2BU, UK

8. Kilifi County Hospital, Kilifi, Kenya

Corresponding author: Louise Downs. Louise.downs@exeter.ox.ac.uk

Keywords: Hepatitis B virus; Patient voice; Lived experience; Barriers to care; Care cascade; Africa;

Kenya; Peer support; Education; Decentralisation; Treatment; Stigma.

Author Contributions

Study conceptualisation and design: LD, JO, MZ, OC, BS, PM

Data curation: LD, JP, MZ, OC, BS, NA, NK

Data analysis: LO, PM, JS, NK

Supervision: JS, PM, NA, NK

Writing – original draft and preparation: LD

Writing – Review and editing: JS, JO, PM, NA, NK

Abstract

Chronic hepatitis B infection (CHB) causes over 1 million deaths annually, with a large burden of

morbidity and mortality in the WHO-African Region (WHO-AFRO) where <5% of people are

diagnosed and 0.2% are on treatment. Studies have shown that understanding of hepatitis B virus

(HBV) here is often poor, and people living with HBV (PLWHB) can experience stigma and

discrimination. However there has been little documentation on the impact of an HBV diagnosis on

the lives of PLWHB in the WHO-AFRO region or community involvement in improving care provision.

We undertook two focus group discussions (FGDs) with PLWHB and two with healthcare workers

(HCWs) providing HBV care at Kilifi County Referral Hospital (KCRH), Kenya to explore experiences of

living with HBV and barriers to accessing care. FGDs were conducted primarily in Kiswahili,

transcribed verbatim and translated into English. The data were analysed thematically using NVivo

version 14.

PLWHB and HCWs at KCRH had a good understanding of HBV which was likely influenced by a

concurrent research study on HBV, however they reported low awareness in the general community,

and there is no local name for the infection. Many PLWHB were shocked at their initial diagnosis with

mixed reactions from friends and family. Costs of transport and concerns about lost employment

were the biggest barriers to care. Many people suggested decentralised clinics would reduce loss to

follow up, however others would rather be treated far from home to preserve anonymity. Stigma

was highlighted as a major issue, leading to feelings of isolation, rejected and discrimination.

Community education, wider testing and advocacy by well-respected community members were

mentioned as key methods to reduce HBV transmission. Decentralisation of clinics may improve

access to care; however, this needs to be developed in careful consultation with PLWHB to ensure

they are acceptable and accessible to all.

Introduction

Approximately 256 million people worldwide are living with chronic hepatitis B infection (HBV) with

the highest burden of infection being in the WHO-African Region (WHO-AFRO) (1). HBV has,

however, been neglected in terms of healthcare provision, education, research and policy (2,3). An

estimated 4.2% of people living with HBV (PLWHB) in WHO-AFRO are diagnosed, and knowledge

around HBV both in communities and healthcare facilities is often limited (1,4). In Kenya, an

estimated 3-5% of the population is living with HBV (5), but screening is largely restricted to those

living with HIV, blood donors, dialysis patients and in some locations antenatal screening. There is

minimal population screening and little vaccination outside of the childhood immunisation series.

Elimination efforts in Kenya are gaining traction with the Ministry of Health working on new HBV

management guidelines and a National Strategic Plan; the community voice along with challenges

faced by healthcare workers (HCWs) in caring for PLWHB must be considered in these efforts.

Throughout the WHO-AFRO region, reports are emerging of the impact of an HBV diagnosis on those

living with the infection, and a new HBV stigma survey has been piloted in selected countries by the

World Hepatitis Alliance (6). It is widely agreed that representation of those with lived experience is

urgently needed to improve representation and advocacy, and inform improved service provision,

which in turn will drive progress towards global elimination targets (7). The positive role of peer

support workers in HBV care is being increasingly recognised, to encourage testing, improve

treatment adherence and reduce stigma (8). Along with this, healthcare workers (HCWs) providing

care for PLWHB have a unique insight into issues including misinformation, stigma and barriers to

long-term follow-up and medication. They also understand the current healthcare infrastructure for

PLWHB, have insights into gaps and challenges, and can advise how access could be improved.

We set out to engage people living with HBV, and HCWs caring for PLWHB in Kilifi County Referral

Hospital (KCRH), Kenya, to generate evidence to inform care delivery, by establishing a platform for

scale up of qualitative data collection in this setting and elsewhere. We convened focus group

discussions (FGDs), aiming to i) explore understanding of HBV infection on an individual and

community level, ii) discuss how the lives of PLWHB have changed since their diagnosis and iii)

investigate barriers to receiving care and consider how these could be reduced. The methods and

results of this study are reported in compliance with the Standards for Reporting Qualitative

Research (SRQR)(9).

Materials and methods

i)   Study context

We conducted FGDs with both PLWHB and HCWs providing HBV services. This study was conducted

at Kilifi County Referral Hospital (KCRH), a referral facility in Coastal Kenya, servicing an area of

around 12 000 km^2 and a population of 1.5 million people. KCRH has 300 inpatient beds and sees

193 000 outpatients every year.   Table 1 summarises the distribution of health facilities in Kilifi

County (10). Poverty levels in Kilifi are above the national average for Kenya, with 53% of the

population living in poverty in 2022 compared to the national average of 40% (11). At the time of this

study, HBV care at KCRH was provided at the Comprehensive Care Clinic (CCC), which is a secondary

care outpatient clinic primarily designed for people living with HIV. The CCC provides adherence

counselling, medication and follow up for both adults and children living with HBV. At KCRH, there is

no routine mechanism for offering further laboratory or imaging assessment to determine HBV

treatment eligibility, therefore standard care is that all those testing HBsAg positive receive

nucleoside analogue (NA) therapy using tenofovir/lamivudine (TDF/3TC) combination therapy. This

approach is in line with conditional recommendations for 'treat all' which are incorporated in new

WHO guidelines released in 2024 (12).

Health Facility Type	Number in Kilifi County
Dispensary	132
Health Centre	18
Public Hospitals	
County Referral Hospital	1
Sub-County Hospital	8
Faith Based Facilities	25
Private, for-profit health facilities	186

Table 1: The distribution of health facilities in Kilifi County, Kenya (10).

ii)   Data collection

We conducted four FGDs, two with PLWHB (consisting of six men and seven women) on 18th June

2024, and two with HCWs (consisting of seven men and seven women) on 14th November 2024.

PLWHB were invited to participate in FGDs during peer support educational sessions initiated by the

CCC matron when coming to pick up medication, and HCWs were invited via a group messaging

platform for CCC staff. Participants were purposively sampled to create groups with diverse ages and

experience, and in the case of HCWs to ensure a spread of cadres involved in HBV service delivery.

FGDs were held in private rooms in the CCC to promote participant privacy. Participants were given a

number from 1-6 or 1-7 within their group to enhance anonymity of the respondents. FGDs with

PLWHB were conducted primarily in Kiswahili by MZ, OC, and BS and facilitated by JO, a member of

the Community Liaison Group from KEMRI Wellcome Trust Research Programme experienced in

qualitative data collection. FGDs with HCWs were conducted in both English and Kiswahili by MZ and

JO, facilitated by LD. Topic guides were used to direct FGDs, informed by study objectives and

literature about patient experiences of accessing and receiving HBV care. The topic guides covered

the understanding of HBV, reactions to diagnosis, the impact on the lives of PLWHB, barriers to care

and how these could be reduced (13). FGDs took around 1.5 hours each, were audio recorded using

an encrypted dictation device from KWTRP, and those participating were given refreshments. PLWHB

attending specifically for the FGDs were compensated lost earnings of around USD $5, as is standard

for community engagement activities at KWTRP.

iii)   STRIKE-HBV partner study

This work was undertaken in collaboration with the STRIKE-HBV study, a research study funded by

the Wellcome Trust, based at KEMRI-Wellcome Trust Research Programme (KWTRP). STRIKE-HBV

offered free HBV testing to all those attending KCRH between March 2023 – May 2024, and free liver

health assessment to anyone living with HBV as previously described (14). STRIKE-HBV enrolled 102

PLWHB, including those newly diagnosed and those already known to be living with HBV and

engaged in care. Activities undertaken by STRIKE-HBV including the status of HBV care in KCRH are

detailed in table 2 and educational material developed for STRIKE-HBV is available online (15). All

PLWHB who took part in these FGDs were also enrolled in STRIKE-HBV.

Category	Prior to STRIKE-HBV	Interventions undertaken by STRIKE-HBV	Situation after STRIKE-HBV
HBV education for staff	None provided. Patients managed in the CCC with no staff training.	Hospital education sessions as part of continuing medical education (CME) and to individual departments, particularly the CCC.	Staff have continued HBV education including reaching out with questions. KCRH is developing hospital specific guidelines for HBV management.
HBV community education	None provided.	- Health talks in Kiswahili detailing HBV symptoms and transmission 3 x week in KCRH OPD. - Information leaflets provided (15) - Education for PLWHB combined with peer support sessions at the CCC.	Staff able to provide improved education to PLWHB and antenatal women regarding HBV testing.
HBV testing	No routine HBV testing either free of charge or paid. No advocacy for testing.	Provision of free HBV testing for non-pregnant adults from March 2023 – June 2024.	HBV testing promoted and offered to antenatal women (although currently at an individual cost)
Peer Support	No peer support for HBV	Nil specific implemented by STRIKE-HBV, but study staff facilitated peer support sessions initiated by the CCC by providing education.	CCC began peer support sessions for PLWHB during STRIKE-HBV and these are continuing following study completion.

141   **Table 2:** Detailing i) Care for people living with HBV (PLWHB) at Kilifi County Referral Hospital (KCRH) prior to

142   the STRIKE-HBV study; ii) Interventions undertaken by the STRIKE-HBV study and iii) Changes in care for PLWHB

143   after STRIKE-HBV completion. Information leaflets were developed in collaboration with the Hepatitis B

144 Foundation (16). CME sessions mostly targeted doctors, nurses, pharmacists and students. OPD – outpatients
145 department; CCC – comprehensive care clinic.
146

iv)   *Data Analysis*

Following FGDs, audio files were transcribed verbatim and translated into English and analysed in

Nvivo version 14. Both inductive and deductive thematic analysis (17) was used to scrutinise the data

to identify and analyse patterns and draw out themes using constant comparison technique (18).

Transcripts from all FGDs were examined on a line-by-line basis and the coding framework was first

developed by LD and refined on discussion with the research team. Codes were developed based on

the original questions asked by the interviewers and areas of interest to the authors, along with new

themes being identified 'a priori' based on existing literature and tailored to the local context (4,19).

v)   *Ethics and governance*

This study was approved by the Scientific Ethics Review Unit (SERU) (SERU 3416). Written consent

was obtained from all FGD participants prior to participation in FGDs, including consent for audio

recording.

Results

Focus groups with PLWHB included six men and seven women with a median age of 37 years (range

24 – 61). Five participants had been newly diagnosed with HBV in the STRIKE-HBV study, eight

already knew their diagnosis prior to enrolment in STRIKE-HBV. Two of those participants who were

newly diagnosed had family members already known to be living with HBV.

HCW focus groups consisted of nine women and five men, with a median age of 31 years (range 18 –

61). The range of cadres included three clinical officers, three community health promotors (CHPs),

two nurses and then one of each: counsellor, adherence supervisor, peer educator, nutritionist,

records officer, and laboratory technician.

*i)   **Knowledge and understanding of HBV***

Both PLWHB and HCWs knew that HBV is a virus causing liver disease and is transmitted sexually or

by contact with infected blood. Sexual transmission was mentioned most by both groups, including

men and women, and still considered the most common route of transmission, especially by PLWHB,

although other routes were mentioned. As participating PLWHB were those already receiving

treatment, they were aware of HBV medication, and some HCWs specifically mentioned the use of

tenofovir/lamivudine combination therapy. In both groups however, there was still some confusion

around what happens after taking treatment for 6 months - some PLWHB thought they would be

cured; however others knew this was not the case:

"In addition, if you have liver disease, you can, if you use the medicine properly for six months

and if you are tested, it may be that the virus is gone", (participant 5, PLWHB, male, FGD 1).

Within the HCW groups, although there was discussion around poor community HBV knowledge,

they also noted a significant knowledge gap amongst HCWs prior to the STRIKE-HBV study. They felt

STRIKE-HBV had given them confidence in HBV management, and that many healthcare providers in

other facilities were still providing incorrect information:

"At first, I didn't know how to give the treatment. I used to just guess. I didn't know how long I

should be giving this medication. I didn't even have the knowledge of package information to

give the patient but right now I can stand comfortably with confidence and tell the patient what

he or she is going to take and for how long the treatment should be and what he or she should

do." (participant 7, HCW, male, FGD 2)

When discussing a local language description of HBV, participants from both groups stated it was an

unknown disease, or only described by the symptoms:

"But this hepatitis B virus is unknown, let's say it has no name. People don't know, they only know

AIDS", (participant 1, PLWHB, female, FGD 2).

"In Kilifi they just describe the complications, when you have jaundice they say "yellow", when

you have ascites they say "mwamimba" [pregnancy], only that." (participant 1, HCW, female,

FGD 2)

Others reported HBV infection was called *'cancer'*. Several people mentioned that they had heard of

HBV as it was causing illness in their village, and perceived it to be a death sentence:

"I knew it [HBV] was killing people in the village. You don't know if he is starting [to get unwell]

but you will only know that something has reached. That is, they don't get medicine, that is, there

is no nursing, it is only when he is taken to the hospital, when he begins to be treated, then death

has already arrived" (participant 6, PLWHB, male, FGD 1).

Several respondents in both HCW and PLWHB groups mentioned that PLWHB were sometimes

thought to be bewitched, and they would go to traditional healers to be cleansed and take herbal

medications instead of tenofovir, or to church to pray to be cured:

"...those [with HBV] who have complications, or have ascites, in local language or native

language we call it "mwamimba" [pregnant] and so they say that they have been bewitched and

somebody has thrown something in their stomach and now like you are like a man but you are

"pregnant". (participant 5, HCW, female, FGD 2).

ii)   Comparison with HIV

Both PLWHB and HCWs discussed the confusion between HBV and HIV, particularly given that care is

received in the same clinic, and the medication is the same. Many PLWHB found it difficult to accept

they did not have HIV, and friends and family sometimes accused them of lying. This was common to

both men and women. Many PLWHB felt they needed to 'prove' they didn't have HIV by going with

family or partners to be tested:

"...one day my wife came and explained to me, "I heard some people say that you have AIDS." I

told her, "No, I don't have AIDS and if you want to know, let's go, let's all go and be tested"

(participant 5, PLWHB, male, FGD 2).

"... [many] people who don't understand and then once they get the results and then they are

being escorted to this building CCC, majority don't get to understand clearly the relationship like

we are telling them it's not HIV and we are giving them ARV's (anti-retroviral therapy)."

(participant 1, HCW, female, FGD 2).

Several times it was mentioned that HIV was better funded than HBV, and there was not the same

level of resources for the two infections.

iii)   **How lives have changed since HBV diagnosis**

We initially discussed reactions to diagnosis, both individually and those of friends and family. Many

PLWHB were shocked at their diagnosis and felt anxious as they had little knowledge of HBV. HCWs

reported many newly diagnosed people thought they were dying, and associated HBV only with end

stage disease. Counselling helped alleviate anxiety and was felt to be very important by both PLWHB

and HCWs. Peer support sessions were motivating and HCWs thought these should be given more

routinely to allow PLWHB to discuss their concerns. Several PLWHB mentioned that once they got

used to their diagnosis, they realised they could continue to take the medication and live just like

anyone else.

Many women diagnosed with HBV had been tested as a condition for travelling abroad for work, and

their diagnosis had not been properly explained to them which caused a lot of distress. They felt lost

and abandoned, unable to pursue their plans, whilst peers and colleagues went off on their travels.

"He [employment agent] refused to tell me because he said [the problem was] either liver or

kidney. I told him, "Now there is no disease that is good and there is no disease which is bad, you

can just explain it to me." He said, "Just go to the doctor and get tested or go and get an x-ray

and he [the other doctor] will explain more, but I won't explain it to you."" (participant 3, PLWHB,

female, FGD 2).

Reactions of friends and family varied. Some were very supportive, went to get tested themselves

and encouraged participants to continue medication, but some partners left after the diagnosis.

Sometimes after an initial lack of understanding, relatives came to the CCC to seek more information

about HBV and its consequences.

Almost all participants commented that their lives had changed since HBV diagnosis, sometimes in

beneficial ways, some less so. One male participant had considerably cut his alcohol consumption

due to concerns about his liver:

"Even that time I came to be tested, I came already drunk…I have been told "The liver's job is this

and this and this and when you eat, the food is processed like this and this and this in the

stomach"… I saw that there is a very important knowledge…. I stopped drinking alcohol; I

continue to take medicine. So I see there is a big change. That is, since I have been drunk all the

time and this time, I can be sober, I'm grateful", (participant 1, PLWHB, male, FGD 1).

Many PLWHB had experienced non-specific symptoms that had improved with treatment such as

tiredness, stomach pains and swelling, nausea, itching, heartburn and constipation. Symptom

improvement with treatment encouraged them to continue:

"I was given about five days [of medication]. I came back, I came and was given for two weeks, I

came back. But since then, I see changes myself even in my body. I don't get hurt a lot and I don't

get a lot of fatigue". (participant 7, PLWHB, female, FGD 1).

"I was diagnosed with this disease, and I just saw that I was already dying. But when I got this

treatment, I am fine now because even when I was sleeping and I could feel my stomach like

water going this way, when I turned over, I could feel like water coming back this way and I said,

"My stomach has started to swell too." But this time when I started this treatment, that issue

stopped and the anxiety of saying that I was dying because I had not received [education]. This

time I have received [education]. Now I know that if I use these drugs properly, I can live

normally." (participant 5, PLWHB, male, FGD 1).

Many participants perceived that they had less freedom as they felt they needed to ensure they

were home from work at a particular time and sometimes decided not to engage in social activities

due to concerns about taking their medication:

"But since I use these drugs, I always tell my friends that I can't walk at night. Because when it

reaches eight o'clock, I have to take medicine" (participant 7, PLWHB, female, FGD 1).

*iv)   **Current provision of HBV care in Kilifi***

We discussed with HCWs what care was available for HBV both in KCRH and further afield, and how

this had changed since the STRIKE-HBV study. Adherence counselling and medication had always

been available at KCRH free of charge for HBV, however as described above, HCWs reported

inadequate knowledge about medication and a lack of confidence when prescribing. In Kilifi County,

diagnosis was most often made in private facilities prior to travel abroad for work, and treatment

was provided primarily at KCRH. Public peripheral facilities and private hospitals often referred

patients to KCRH as it was known to have an established hepatitis clinic. Occasionally people would

be able to pick up their medication from subcounty hospitals and smaller health centres, but only

after education and service establishment by HCWs from KCRH:

"So, there were no services [no hepatitis clinic] there, but we had to recreate the services for her

to get the drugs. So, some have opted to go to a smaller health centre, and some to two sub-

county hospitals, and so we have some sites which are offering [HBV treatment] but the diagnosis

was done here." (Participant 7, HCWs, male, Group 2).

The HCWs however still perceived that peripheral facilities require more support to increase their

confidence in providing HBV care. Many health centres and dispensaries had HBV medication

available along with adherence counsellors as they cared for those living with HIV, yet patients who

desired to get their treatment from their nearby facilities were sometimes still referred upwards to

KCRH:

"...as much as they wish to go there, some facilities have limited knowledge on client follow up

and now it becomes a challenge, but we have clients who would prefer to take medication from a

nearby facility. I have had two who have been returned [to KCRH from peripheral facilities] for

further management because the dispensary is not well equipped to manage hepatitis clients."

(FGD 2, HCWs, female, participant 1).

Since STRIKE-HBV, HCWs reported they were able to provide better informed psychosocial support

for PLWHB. They also encouraged PLWHB to talk to partners and family about testing to try to reduce

stigma. They reported encouraging PLWHB to be ambassadors and educate the community about

HBV and some HCWs were sharing their improved HBV knowledge with colleagues in peripheral

facilities to support them in providing HBV care.

v)   Barriers to HBV care and how these can be reduced

a.   Economic Factors

Economic factors seemed to be the biggest barrier to receiving care. Firstly, the cost of transport to

attend a distant hospital-based clinic was mentioned by both HCWs and PLWHB. To counter this cost,

many people felt HBV medication should be available at the local dispensary:

"Because the rest of us are far away [from the hospital], but if we find our local dispensaries

nearby, these local medicines, the way we are known, they are placed there. It will be easy

even for us because we won't have to pay fare", (participant 2, PLWHB, female, FGD 1).

"…they come from far and first they have the transport issues and secondly they are living in

abject poverty and so most of them they cannot make it to Kilifi and so at least if we have the

resources [medication] and we dispense the resources [medication] nearer to them then it

will be better." (participant 7, HCWs, male, FGD 2).

Several PLWHB mentioned the need to plan to make sure they had fare to attend clinic. Along with

fare, the timing of clinic appointments had little flexibility, and often the patients experienced long

waiting times. This was difficult with employment, with men in particular mentioning they struggled

to get days off work leading to lost earnings:

"So the challenge always arises because maybe your boss refuses to agree with you, maybe it

[the clinic return date] can be balanced until you get the chance to come take medicine or a

meeting like this. You may find that your boss telling you, "Now you might not get paid today,

or we will remove this day from your rest days, we will cut it there". (Participant 5, PLWHB,

male, FGD 2).

The wish for decentralised clinics however was not universal. Several people in both the patient and

HCW groups mentioned that (despite the potential higher cost) some PLWHB would prefer to go to a

distant clinic (where they are not known) to reduce stigma, and sometimes asking for money for

transport caused problems with questions about where they were going:

"…many of them still have stigma so they are thinking like if I am seen there, I will be

isolated, so many prefer to go to those far away hospitals that no one knows, very few said

they were referred to go to a nearby hospital." (Participant 4, HCW, female, FGD 1).

"[If I ask a friend]: Help me with 200 shillings ($1.5) so that I can go somewhere and then I

will give you back." He asks, "Where do you want to go?" What do you want to do with it?"

Now that's where I see the difficulty." (Participant 5, PLWHB, male, FGD 1).

b. **Stigma and lack of education**

Stigma was raised as an issue by all focus groups, both men and women, with participants

highlighting instances of self-stigma and community stigma. Concerning self-stigma, PLWHB felt they

were being talked about, and others were distancing themselves for fear of infection:

"And if the food itself I can't eat with them at the same table, it is as if I will infect them, I

should have my own bowl and sit aside", (participant 3, PLWHB, female, FGD 1).

As noted earlier, HIV and HBV services are currently integrated in KCRH and all clients are seen

together in the same clinic. PLWHB revealed tensions around this, with some participants feeling

they should have a separate clinic from those living with HIV, partly due to stigma when seen

entering the HIV clinic, but also due to long wait times when being seen together. Some people felt

those living with HIV were prioritised, although there was also agreement that separating those with

HBV and HIV could increase stigma, and they should all be together because they had more in

common than differences:

"I see they should just be together because we cannot separate them [HIV patients]. We all say

we are birds of the same colour, we are going in the same direction. It means that if we separate

them, it is like we are bringing that stigma and we don't want it to be like that", (participant 2,

PLWHB, male, FGD 2).

Education was seen by both PLWHB and HCWs as the best way to combat stigma, including

continuing education for PLWHB through expert led peer support sessions, along with informing the

immediate family and community. Several people mentioned initiatives on television or the radio to

spread information about HBV, and respected community members such as pastors and chiefs to

encourage testing and treatment. Several people in the HCW group felt the community health

promotors (CHPs) could play a pivotal role in HBV sensitisation and treatment adherence. They

mentioned how CHPs are funded to visit people living with HIV at home but not those living with

HBV:

"I feel the CHP should also be brought on board on issues of Hepatitis B sensitisation and

treatment adherence. Because you will get CHP bringing a referral or a patient who had

defaulted treatment for [HIV treatment] but they will never do follow up for a client with

Hepatitis." (Participant 1, HCW, female, FGD 2).

vi)   Reducing transmission

When asking PLWHB how to reduce HBV transmission, practical ways were discussed to reduce

contact with the virus including safe sexual practices, and one participant mentioned wearing gloves

before helping anyone who was injured. Reducing the sharing of instruments that spread HBV was

felt to be important, particularly needles, razors and toothbrushes, and a few participants mentioned

vaccination, but did not distinguish groups they felt could benefit from vaccination, or how

vaccination should be offered.

Both PLWHB and HCWs felt that community awareness is paramount in stopping the spread of HBV,

including reducing fears of testing by educating people that HBV can be managed well with

medication, which is available free of charge, and is not a death sentence. Participants suggested

testing could be promoted through TV and radio campaigns, by religious leaders and the Ministry of

Health:

"So you find when people already know that [HBV can be dangerous], if the pastors also

intervene, after explaining, now you will get a large group that say, "Uh, let me look at myself."

And there I think we will find many people will volunteer [for HBV testing]. You can't go to

someone's house and grab his shirt and bring him here, no, it's up to him to decide and say, "At

my own free will, let me check."", (participant 6, PLWHB, male, FGD 2).

Access to testing was also mentioned by several PLWHB, ensuring the community knows this is

available, where to be tested and ideally testing being offered for free. Many HCWs and PLWHB

discussed that HBV testing should be part of the routine screening that everyone has when they go

to a hospital, like HIV. There was also discussion of the benefits of antenatal testing for HBV, and how

this should be routine:

"… There should be free testing, random or all over, everyone to be reached. I can say here in

Kilifi, the people of Kilifi are lucky because even I am lucky because of your research and the

services that are provided here." (participant 3, PLWHB, female, FDG 1).

"…perhaps if the pregnant mother it is her first time, she must come with her husband so that

they can be tested for AIDS, and the likes. Now I was thinking it would also be good if this

hepatitis B was placed in that category, when they come to be tested, if she has come to the

clinic, being tested for the HIV virus, they should also test the Hepatitis B virus…", (participant 6,

PLWHB, male, FGD 2)

Reducing stigma around an HBV diagnosis was felt to be key in reducing transmission. If those living

with HBV felt able to reveal and discuss their diagnosis, they could also be the ones to spread

awareness and educate their communities:

"I think it would be better for those of us who have the disease to not be ashamed. I explain that

I was diagnosed with that disease [HBV] and that I use those drugs, I tell the people there to go

to the hospital, not to wait until the organisation reaches the grassroots, it will be too late",

(participant 4, PLWHB, male, FGD 2).

A common theme that ran through all the discussion questions was lack of education. Improved HBV

awareness and knowledge was seen as crucial in all areas including reducing stigma, reducing

Knowledge and understanding	How lives have changed	Current care available	Barriers to care	How to reduce transmission and improve care

transmission, improving testing and diagnoses and improving access to care. Both PLWHB and HCWs

highlighted this throughout as paramount to improve the lives of PLWHB in Kenya.

Discussion

We set out to explore the experiences of both PLWHB and HCWs providing HBV care in Kilifi Kenya

aiming to understand HBV knowledge, impact of HBV on people's lives and barriers to accessing care.

Our findings, summarised in Table 3, add to the limited literature exploring the lives of PLWHB in

WHO-AFRO countries. Several studies have evaluated different mechanisms to try and improve HBV

care, however very few have included the patient voice, or discussed with HCWs involved with

patient care when planning interventions, making this a valuable addition to HBV literature (20,21).

Ongoing confusion about medication duration after the initial 6-month period.	Unable to travel abroad due to HBV diagnosis.	Adherence counselling and psychosocial support provided at KCRH.	Economic factors - Cost of transport - Lack of decentralised clinics - Living in poverty - Loss of work - Difficulties getting time off work to attend	- Education about safe sexual practices. - Reduce sharing of household implements (razors/toothbrushes) - Provision of vaccination including birth dose vaccine.
Poor community knowledge with no local language word for HBV	Reduced alcohol intake and better self-care.	Staff at KCRH educate partners and family.		Community educational campaigns.
HCWs poorly informed prior to STRIKE-HBV and incorrect information still given in other facilities	Less freedom in the evenings to meet friends due to medication timing.	Testing not free of charge outside of STRIKE-HBV.	Stigma and lack of education - Self-stigma and community stigma	TV and radio campaigns, advocacy by prominent society members and the ministry of health.
PLWHB concerns about being 'bewitched' and visiting traditional healers to be 'cured'.	Concerns about dying.	No vaccination provided other than the routine infant schedule.	- Concerns from others about transmission - Unhappy about HIV/HBV service integration due to increased stigma.	Better availability of free testing, particularly in antenatal women. Testing available in communities.
Confusion with HIV. Many PLWHB having to 'justify' to relatives they don't have HIV.		Smaller facilities have the correct provisions but feel unable to provide HBV care due to lack of knowledge	Lack of freely available testing and vaccination.	Decentralised clinics for those who want them, and education of more HCWs.
				Specific hepatitis clinics, separate from HIV.

Table 3: Summary of the different themes arising from focus group discussions (FGDs) with people living with

hepatitis B virus infection (PLWHB) and healthcare workers (HCWs) caring for PLWHB at Kilifi County Referral

Hospital (KCRH) in Kilifi, Kenya. HBV – hepatitis B virus.

Financial barriers have also been highlighted elsewhere (22–24), and can lead to catastrophic costs

for individuals and families living with HBV (25). In our study, travel costs to the hospital clinic were

seen as most prohibitive, whereas in studies from Burkina Faso and Ghana, costs of tests, monitoring

and medications were mentioned more commonly (23,26). This may be because in our study testing

and nucleoside analogue therapy were provided free at the point of care in KCRH which is not the

case in many other countries. Many studies both from within WHO-AFRO and elsewhere have raised

concerns around lost employment (27–29) as in our study, and this was particularly common

amongst men. Lack of childcare was mentioned as a significant barrier to care in some studies

outside of WHO-AFRO (28). This was not mentioned at all in our study or others from Ghana or

Burkina Faso (23,24) possibly due to the different family structures in countries in WHO-AFRO

compared to those in the Global North, with less reliance on parents being the sole care givers.

The concerns raised by our participants around the integration of HBV and HIV care particularly

related to increased stigma has been discussed previously (30). The utilisation of existing HIV services

is one of the key components hypothesised to enable decentralisation of HBV care. However, we

suggest that caution is needed, and extensive community education and sensitisation should be

done before this is implemented. We also found that there is often confusion between HIV and HBV,

which was also the case in Burkina Faso where HBV was closely associated with HIV when explained

to patients (23). Although this was seen as a negative association, the good understanding of HIV

transmission routes did help explain HBV transmission. In Burkina Faso, those diagnosed with HBV

outside of a hospital setting were often given poor information around HBV, similar to several of our

PLWHB who were diagnosed pre-travel.

An interesting finding in our study was that many PLWHB felt they were restricted in the evenings

due to taking medication, having to be home from work at a particular time or being unable to meet

friends. This has been described in HIV literature as people are more likely to take their medication at

home and do not want to carry tablets with them due to fear of discovery (31). It may also be that

the HBV clinic has given instructions around when to take medication related to food to reduce side

effects, and this is most convenient in the evenings. Education from the HBV clinic around the

flexibility of medication timing could be helpful, so PLWHB understand it can take be taken at any

time of day as long as this is consistent and does not need to interfere with any other social,

domestic or work commitments.

Several suggestions from participants here on how to improve care are already included in national

Kenyan guidelines on the management of HBV such as antenatal HBV testing and provision of

vaccination to close family contacts (32), however these are not universally incorporated into care. To

continue strengthening HBV care at KCRH and across the County, ensuring education is a funding

priority is crucial. Education was seen as one of the most important initiatives to increase diagnoses,

drive down stigma and improve HBV care pathways. As HCWs frequently transfer between facilities,

even localised educational initiatives have the potential to disseminate knowledge more broadly.

Caveats and limitations

We only included PLWHB in this study who were already linked to care and receiving treatment, and

both HCWs and PLWHB had been involved in previous research and have engaged with a peer

support group. These groups are likely to have better knowledge and PLWHB be more engaged in

care than those not involved in such a study. Here we included people from a limited geographical

area and only a small number of HCWs and PLHWB. To fully understand care barriers, we need to

undertake similar discussions with PLWHB who have been lost to follow up, those not offered

treatment and include community groups not tested or living with HBV; ideally a future study would

expand to include PLWHB and HCWs accessing healthcare services both in Kilifi and further afield.

Conclusions

Community education and decentralisation of care for PLWHB should be prioritised to reduce stigma,

enable easier access to care, reduce travel times and costs to reduce health inequities and support

wider roll-out of treatment. Community co-design is critical to ensure interventions are appropriate,

accessible, acceptable and affordable, and can be sustained over time.

Acknowledgements

We would like to thank all the PLWHB and HCWs who took part in these FGDs, along with the CCC

team for facilitating the use of their clinic space to undertake this work. Without their enthusiasm

and dedication to improving care for those living with HBV, this would not have been possible.

Data Availability

Full recordings and transcripts in both English and Kiswahili of these FGDs are held on a secure server

at KWTRP but could be accessed by other studies on request to dgc@kemri-wellcome.org and

approval by the data governance committee. For the purpose of Open Access, the author has applied

a CC-BY public copyright license to any author accepted manuscript version arising from this

submission. This manuscript was written with the permission of Director KEMRI CGMRC.

Conflicts of Interest

PCM has previously received funding from GSK for a PhD student in her group. This has had no

influence over the planning or undertaking of the study, the writing of the manuscript or decision to

publish.

References

1.   Global hepatitis report 2024: action for access in low- and middle-income countries [Internet].
World Health Organization; 2024 [cited 2024 Jun 4]. Available from:
https://www.who.int/publications/i/item/9789240091672

2.   O'Hara GA, McNaughton AL, Maponga T, Jooste P, Ocama P, Chilengi R, et al. Hepatitis B virus
infection as a neglected tropical disease. PLoS Negl Trop Dis [Internet]. 2017 Oct 5;11(10).
Available from: http://dx.doi.org/10.1371/JOURNAL.PNTD.0005842

3.   Delphin M, Mohammed KS, Downs LO, Lumley SF, Waddilove E, Okanda D, et al. Under-
representation of the WHO African region in clinical trials of interventions against hepatitis B
virus infection. Lancet Gastroenterol Hepatol. 2024 Feb 15;9(4):383–92.

4.   Mugisha J, Mokaya J, Bukenya D, Ssembajja F, Mayambala D, Newton R, et al. A Study of
Knowledge, Experience, and Beliefs About Hepatitis B Virus (HBV) Infection in South Western
Uganda. Front Public Health. 2019 Oct 25;7:304.

5. Polaris Observatory Collaborators. Global prevalence, cascade of care, and prophylaxis coverage
of hepatitis B in 2022: a modelling study. Lancet Gastroenterol Hepatol. 2023 Oct;8(10):879–
907.

6. Hepatitis Stigma Survey - World Hepatitis Alliance [Internet]. World Hepatitis Alliance - Fighting
for a world free from viral hepatitis. World Hepatitis Alliance; 2023 [cited 2025 Jan 24].
Available from: https://www.worldhepatitisalliance.org/stigma/

7. Matthews PC, Jack K, Wang S, Abbott J, Bryce K, Cheng B, et al. A call for advocacy and patient
voice to eliminate hepatitis B virus infection. Lancet Gastroenterol Hepatol. 2022 Apr;7(4):282–
5.

8. Downs LO, Kabagambe K, Williams S, Waddilove E, Delphin M, Lumley SF, et al. Peer support for
people living with hepatitis B virus-A foundation for treatment expansion. J Viral Hepat
[Internet]. 2024 May 26; Available from: http://dx.doi.org/10.1111/jvh.13952

9. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative
research: a synthesis of recommendations. Acad Med. 2014 Sep;89(9):1245–51.

10. Tsofa B, O. L. , Ngala T, et al. ,, Kilifi county health sector review. *County Integrated Development
Plan 2023-2027: Accelerating Socioeconomic Transfromation for Inclusive Growth*. 2023.
[Internet].   Available   from: https://kilifiassembly.go.ke/wp-
content/uploads/2023/03/CIDP_III_Revised_Draft_1732023-Malindi_230329_162427.pdf

11. Kilifi   County   Data   &   Stats   [Internet].   [cited   2025   Jan   10].   Available   from:
https://statskenya.co.ke/county-information/Kilifi/3

12. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B
infection [Internet]. World Health Organization; 2024 [cited 2024 Apr 26]. Available from:
https://www.who.int/publications/i/item/9789240090903

13. Downs LD, Matthews PM, Kagwanja NK. Focus group discussion guides used to facilitate
discussions with people living with hepatitis B virus infection (PLWHB) and healthcare workers
managing PLWHB in Kilifi, Kenya [Internet]. figshare; 2025 [cited 2025 Mar 3]. Available from:
http://dx.doi.org/10.6084/m9.figshare.28350341.v1

14. Downs LO, Chirro O, Zaharani M, Safari B, Okanda D, Githinji G, et al. STRIKE-HBV: establishing
an HBV screening programme in Kilifi, Kenya-challenges, successes and lessons learnt. Sex
Transm Infect [Internet]. 2024 May 24; Available from: http://dx.doi.org/10.1136/sextrans-
2024-056163

15. Downs L. Documents produced when setting up the STRIKE-HBV study including patient
information leaflets and posters in English and Kiswahili [Internet]. figshare; 2024 [cited 2024
Nov 28]. Available from: http://dx.doi.org/10.6084/m9.figshare.25132256.v1

16. Home » Hepatitis B Foundation [Internet]. [cited 2025 Jan 21]. Available from:
https://www.hepb.org/

17. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006 Jan 1;3(2):77–
101.

18. Glaser BG, Strauss AL. The discovery of grounded theory: Strategies for qualitative research. 1st
Edition. Routledge; 2017. 282 p.

19. Chen T, Borondy-Jenkins F, Zovich B, Block SJ, Moraras K, Chan A, et al. Existing knowledge,
myths, and perceptions about hepatitis B and liver cancer within highly impacted immigrant
communities. J Virus Erad. 2024 Jun 14;10(2):100379.

20. Wong RJ, Khalili M. A patient-centered hepatitis B virus (HBV) educational intervention
improves HBV care among underserved safety-net populations. J Clin Gastroenterol. 2020
Aug;54(7):642–7.

21. Jonas MC, Sheu Y-S, Wright K, Peyton L, Bishop RC, Basra S, et al. A care coordination program
to support patients with hepatitis B virus at Kaiser Permanente Mid-Atlantic States. BMC Health
Serv Res. 2024 Apr 18;24(1):482.

22. Lu J, Xu A, Wang J, Zhang L, Song L, Li R, et al. Direct economic burden of hepatitis B virus
related diseases: evidence from Shandong, China. BMC Health Serv Res. 2013 Jan 31;13(1):37.

23. Giles-Vernick T, Hejoaka F, Sanou A, Shimakawa Y, Bamba I, Traoré A. Barriers to Linkage to Care
for Hepatitis B Virus Infection: A Qualitative Analysis in Burkina Faso, West Africa. Am J Trop
Med Hyg. 2016 Dec 7;95(6):1368–75.

24. Adjei CA, Naab F, Donkor ES. Beyond the diagnosis: a qualitative exploration of the experiences
of persons with hepatitis B in the Accra Metropolis, Ghana. BMJ Open. 2017 Nov
3;7(11):e017665.

25. Jemutai J, Downs L, Anderson M, Cohen C, Seeley J, Sultan B, et al. Elimination of hepatitis B
requires recognition of catastrophic costs for patients and their families. Lancet Gastroenterol
Hepatol. 2025 Feb;10(2):100–3.

26. Adjei CA, Stutterheim SE, Naab F, Ruiter RAC. Chronic Hepatitis B stigma in Ghana: a qualitative
study with patients and providers. BMJ Open. 2019 Jun 27;9(6):e025503.

27. Freeland C, Farrell S, Kumar P, Kamischke M, Jackson M, Bodor S, et al. Common concerns,
barriers to care, and the lived experience of individuals with hepatitis B: a qualitative study.
BMC Public Health. 2021 May 28;21(1):1004.

28. Tang LY, Pene F, Cherfas L, Schwartz J, Baquero MC. Facilitators and barriers to accessing
hepatitis B care in the postpartum period among foreign-born New Yorkers: a qualitative
analysis of case notes. BMC Public Health. 2024 Jan 8;24(1):116.

29. Taheri Ezbarami Z, Hassani P, Zagheri Tafreshi M, Alavi Majd H. A qualitative study on individual
experiences of chronic hepatitis B patients. Nurs Open. 2017 Oct;4(4):310–8.

30. Mutyoba JN, Wandera C, Ejalu D, Seremba E, Beyagira R, Amandua J, et al. Feasibility and
acceptability of integrating hepatitis B care into routine HIV services: a qualitative study among
health care providers and patients in West Nile region, Uganda. BMC Health Serv Res. 2023 Jan
20;23(1):59.

31. Audi C, Jahanpour O, Antelman G, Guay L, Rutaihwa M, van de Ven R, et al. Facilitators and
barriers to antiretroviral therapy adherence among HIV-positive adolescents living in Tanzania.
BMC Public Health. 2021 Dec 13;21(1):2274.

32. Kenyan Ministry for Health. Kenyan Ministry for Health Guidelines Immunisation.pdf. 2023 Apr.